Quick Answer
Boron Bone Health Randomized Trial has evidence relevant to benefits, uncertainty, and practical interpretation, but conclusions should stay close to the cited sources. One representative finding is: Boron neutron capture therapy (BNCT) is a biologically targeted, high-linear energy transfer radiotherapy that selectively delivers cytotoxic α-particles to boron-loaded tumor cells and has re-emerged with the development of hospital-compatible accelerator neutron sources and improved boron carriers.
Key Takeaways
- 01Boron neutron capture therapy (BNCT) is a biologically targeted, high-linear energy transfer radiotherapy that selectively delivers cytotoxic α-particles to boron-loaded tumor cells and has re-emerged with the development of hospital-compatible accelerator neutron sources and improved boron carriers. [Kutuk T (2026)]
- 02We performed a structured literature review of PubMed, Embase, and the Cochrane Library through October 2025 to summarize the radiobiological rationale, boron delivery strategies, and clinical outcomes of BNCT in glioblastoma (GBM) and other high-grade central nervous system tumors. [Kutuk T (2026)]
- 03We previously reported that, in a randomized, double-blind clinical trial with 180 healthy infants, an A2 β-casein IF containing high sn-2 palmitate levels, and casein phosphopeptides (CPP) improved stool consistency, gastrointestinal comfort, crying time, and bone mineral density. [Wang L (2026)]
- 04Relative to standard cow's milk IF, the A2 β-casein, high sn-2 palmitate and CPP IF reduced fatty acid and calcium excretion, reduced calcium fatty acid soap formation, increased hair iron and zinc content, and was associated with lower cortisol levels. [Wang L (2026)]
The current Migaku evidence database contains 2 reusable source documents for Boron Bone Health Randomized Trial. This answer focuses on benefits, uncertainty, and practical interpretation.
- Boron neutron capture therapy (BNCT) is a biologically targeted, high-linear energy transfer radiotherapy that selectively delivers cytotoxic α-particles to boron-loaded tumor cells and has re-emerged with the development of hospital-compatible accelerator neutron sources and improved boron carriers. [Kutuk T (2026); evidence level 4]
- We performed a structured literature review of PubMed, Embase, and the Cochrane Library through October 2025 to summarize the radiobiological rationale, boron delivery strategies, and clinical outcomes of BNCT in glioblastoma (GBM) and other high-grade central nervous system tumors. [Kutuk T (2026); evidence level 4]
- We previously reported that, in a randomized, double-blind clinical trial with 180 healthy infants, an A2 β-casein IF containing high sn-2 palmitate levels, and casein phosphopeptides (CPP) improved stool consistency, gastrointestinal comfort, crying time, and bone mineral density. [Wang L (2026); evidence level 4]
- Relative to standard cow's milk IF, the A2 β-casein, high sn-2 palmitate and CPP IF reduced fatty acid and calcium excretion, reduced calcium fatty acid soap formation, increased hair iron and zinc content, and was associated with lower cortisol levels. [Wang L (2026); evidence level 4]
- Infant formula (IF) is essential when breastfeeding is not possible or sufficient. [Wang L (2026); evidence level 4]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources